Rural

Rural is a biotechnology company focused on developing innovative therapies for metabolic diseases, including type 2 diabetes and obesity. The company leverages its expertise in peptide chemistry and small molecule design to create next-generation incretin mimetics. Their lead programs target the glucagon-like peptide 1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) to improve glycemic control and promote weight loss. Rural aims to address the growing global burden of metabolic disorders through highly potent and selective therapeutic candidates. The company is currently advancing its pipeline through pre-clinical validation and optimization.